Raffles Associates LP’s Lineage Cell Therapeutics In Position
Does Raffles Associates LP own Lineage Cell Therapeutics In (LCTX)? Yes — 5.36M shares worth $8M (+7.35% of its 13F portfolio) as of Q1 2026.
Position Value
$8M
Q1 2026
Shares
5.36M
% of Portfolio
+7.35%
Quarters Held
21
currently held
Position History LCTX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 5.36M | $8M | +7.35% |
| Q4 2025 | 5.36M | $9M | +6.72% |
| Q3 2025 | 5.39M | $9M | +8.48% |
| Q2 2025 | 5.39M | $5M | +5.10% |
| Q1 2025 | 5.64M | $3M | +3.10% |
| Q4 2024 | 5.49M | $3M | +2.97% |
| Q3 2024 | 4.51M | $4M | +4.19% |
| Q2 2024 | 4.36M | $4M | +4.90% |
| Q1 2024 | 3.21M | $5M | +5.51% |
| Q4 2023 | 2.13M | $2M | +2.94% |
| Q3 2023 | 1.59M | $2M | +2.48% |
| Q2 2023 | 1.60M | $2M | +3.03% |
| Q1 2023 | 1.54M | $2M | +3.14% |
| Q4 2022 | 1.54M | $2M | +2.10% |
| Q3 2022 | 2.08M | $2M | +2.51% |
| Q2 2022 | 1.93M | $3M | +3.32% |
| Q1 2022 | 1.31M | $2M | +2.07% |
| Q4 2021 | 543.6K | $1M | +1.28% |
| Q3 2021 | 93.6K | $236,000 | +0.22% |
| Q2 2021 | 43.6K | $124,000 | +0.11% |
| Q1 2021 | 43.6K | $102,000 | +0.10% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Raffles Associates LP’s full portfolio or all institutional holders of LCTX.